deltatrials
Recruiting PHASE1 NCT06969612

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

A Prospective, Phase IB Clinical Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Sponsor: Peking University Cancer Hospital & Institute

Conditions NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions Albumin Paclitaxel Carboplatin Cisplatin Golidocitinib Paclitaxel Pemetrexed Tislelizumab
Updated 2 times since 2025 Last updated: Jun 3, 2025 Started: May 15, 2025 Primary completion: May 31, 2027 Completion: May 31, 2028

This PHASE1 trial investigates NSCLC (Advanced Non-small Cell Lung Cancer) and is currently actively recruiting participants. Peking University Cancer Hospital & Institute leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

2 versions recorded

  1. Jul 2025 — Present [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  2. Jun 2025 — Jul 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

May 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Peking University Cancer Hospital & Institute
Data source: Peking University Cancer Hospital & Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Beijing, China